Jefferies analyst Clara Dong has maintained their bullish stance on COGT stock, giving a Buy rating today.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Clara Dong has given her Buy rating due to a combination of factors that highlight Cogent Biosciences’ promising outlook. The recent results from the PEAK 2L GIST trial were particularly impressive, showing that the combination of bezuclastinib and Sutent nearly doubled the median progression-free survival compared to Sutent alone. This significant improvement in efficacy positions the combination as a potential new standard of care in the second-line treatment of GIST, a market with limited competition and substantial growth potential.
Additionally, the trial demonstrated a favorable safety profile, with manageable side effects that are unlikely to hinder clinical adoption. The broad mutation coverage of the combination therapy further enhances its appeal, allowing physicians to initiate treatment without waiting for mutation testing. These factors, coupled with the company’s strategic plans to file for regulatory approval in the first half of 2026, support the expectation of rapid commercial scaling, leading to an increased price target for Cogent Biosciences’ stock.
In another report released today, LifeSci Capital also maintained a Buy rating on the stock with a $53.00 price target.